Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation (FLR) by Berger Montague on behalf of investors who acquired shares between February 18, 2025, and July 31, 2025, alleging that the company concealed significant cost overruns and execution problems on key infrastructure projects [1][3]. Company Overview - Fluor Corporation, headquartered in Irving, Texas, provides engineering, procurement, construction, and project management services globally, with its Urban Solutions segment being the largest revenue driver among its three segments [2]. Allegations and Issues - The lawsuit claims that FLR concealed substantial cost overruns and execution issues on major projects, including the Gordie Howe International Bridge and I-635/LBJ, which were affected by subcontractor errors, supply chain inflation, and construction delays [3]. - The company allegedly overstated its risk mitigation strategies while failing to disclose the full impact of reduced client spending and macroeconomic uncertainties [3]. Financial Performance - Despite the ongoing issues, FLR reaffirmed its financial guidance in May 2025. However, on August 1, 2025, the company reported second-quarter results that significantly missed expectations, with non-GAAP EPS of $0.43 (missing by $0.13) and revenue of $3.98 billion (missing by $570 million) [4]. - Following these disappointing results, FLR cut its full-year guidance, leading to a 27.04% drop in stock price to $41.42 on August 1, 2025, prompting analysts to downgrade the stock due to lost confidence in management's disclosures and project oversight [4].

Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation (FLR) for allegedly concealing significant cost overruns and execution problems on key infrastructure projects, leading to a sharp decline in stock value and investor confidence [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased FLR shares between February 18, 2025, and July 31, 2025 [1][2]. - Investors have until November 14, 2025, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Company Background - Fluor Corporation, headquartered in Irving, Texas, provides engineering, procurement, construction, and project management services globally, with its Urban Solutions segment being the largest revenue driver [2]. Group 3: Allegations and Financial Impact - FLR is accused of hiding cost overruns and execution issues on major projects, including the Gordie Howe International Bridge and I-635/LBJ, due to subcontractor errors, supply chain inflation, and construction delays [3]. - The company allegedly overstated its risk mitigation strategy and failed to disclose the impact of reduced client spending and macroeconomic uncertainty [3]. - Despite these issues, FLR reaffirmed its financial guidance in May 2025, but reported disappointing second-quarter results on August 1, 2025, with non-GAAP EPS of $0.43 (missing by $0.13) and revenue of $3.98 billion (missing by $570 million) [4]. - Following these disclosures, FLR's stock fell by 27.04% to a closing price of $41.42, leading to analyst downgrades due to lost confidence in management [4].

Core Points - Berger Montague PC is investigating claims against KinderCare Learning Companies, Inc. following a class action lawsuit related to the company's failure to disclose incidents of child abuse and neglect at its facilities [1][3] - The lawsuit alleges that the IPO registration statement did not reveal numerous incidents of harm that occurred at KinderCare, with a report from The Bear Cave highlighting these issues [3] - KinderCare's shares have significantly declined, losing approximately 60 percent of their value since the IPO [4] Summary by Sections Company Overview - KinderCare Learning Companies, Inc. is a provider of early childhood education and childcare services [1] Legal Issues - A class action lawsuit has been filed against KinderCare, with allegations that the company failed to disclose serious incidents of child abuse and neglect [3] - Investors who purchased KinderCare securities between October 6, 2024, and August 12, 2025, have a deadline of October 14, 2025, to seek appointment as lead plaintiff [2] Financial Impact - Following the IPO, KinderCare's shares have experienced a significant decline, losing about 60 percent of their value at the time of the lawsuit filing [4]

Core Viewpoint - A class action lawsuit has been filed against V.F. Corporation (VFC) by Berger Montague PC on behalf of investors who purchased shares between October 30, 2023, and May 20, 2025, alleging that the company misled investors regarding its brand recovery efforts, particularly for the Vans brand [1][3]. Group 1: Lawsuit Details - The lawsuit claims that VFC made positive statements about its brand recovery while concealing significant reset measures that were already in progress [3]. - Investors who acquired VFC securities during the class period have until November 12, 2025, to seek appointment as lead plaintiff representatives [2]. Group 2: Financial Performance - On May 21, 2025, VFC reported a 20% revenue decline for the Vans brand in Q4 of fiscal 2025, following an 8% decline in the previous quarter [4]. - The company attributed part of this revenue shortfall to restructuring and revenue-reduction strategies that had not been publicly communicated, indicating that even without these actions, Vans would have faced a high single-digit revenue decline [4]. Group 3: Market Reaction - Following the disclosure of the revenue decline, VFC shares fell over 15%, dropping from $14.43 per share on May 20, 2025, to $12.15 per share on May 21, 2025 [5].

Accessibility StatementSkip Navigation Following this disclosure, CTO stock fell nearly 6%, closing at $17.10 per share on June 25, 2025. If you are a CTO investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865. About Berger MontagueBerger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, C ...

Core Viewpoint - A class action lawsuit has been filed against Altimmune Inc. by Berger Montague PC on behalf of investors who acquired Altimmune securities between August 10, 2023, and June 25, 2025, following disappointing trial results for its drug Pemvidutide [1][2][3]. Company Overview - Altimmune Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, focusing on therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) [2]. Legal Action Details - The lawsuit is based on a press release issued by Altimmune on June 26, 2025, which announced that the IMPACT Phase 2b trial of Pemvidutide failed to achieve statistical significance in its primary endpoint related to fibrosis reduction, attributed to a higher-than-expected placebo response [3]. - Following the announcement, Altimmune's stock price plummeted by 53.2%, dropping from a close of $7.71 on June 25, 2025, to $3.61 on June 26, 2025 [4]. Investor Information - Investors who purchased Altimmune securities during the class period have until October 6, 2025, to seek appointment as lead plaintiff representatives [2].

, /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against LifeMD, Inc. (NASDAQ: LFMD) ("LifeMD" or the "Company") on behalf of investors who purchased or acquired shares during the period from May 7, 2025 through August 5, 2025 (the "Class Period"). Investor Deadline: Investors who purchased or acquired LifeMD securities during the Class Period may, no later than October 27, 2025, seek to be appointed as a lead plaintiff representative of the class. To lea ...

Group 1 - The core issue involves Berger Montague PC investigating claims against CTO Realty Growth, Inc. for allegedly misleading investors regarding its financial condition and overstating property profitability [1][2]. - The lawsuit claims that CTO manipulated key financial metrics and misrepresented the performance of properties, particularly Ashford Lane in Atlanta [2]. - A report by Wolfpack Research accused CTO of covering a $38 million dividend shortfall by diluting shareholders through a 70% increase in outstanding shares and using a "sham loan" to conceal issues with a tenant [3]. Group 2 - Investors who acquired CTO securities between February 18, 2021, and June 24, 2025, have until October 7, 2025, to seek appointment as lead plaintiff in the class action [2]. - Following the allegations, CTO's stock experienced a decline of 5.42%, closing at $17.10 per share on June 25, 2025 [3].

Core Points - National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. for the period between March 17, 2022, and September 22, 2022 [1][3] - The class action lawsuit alleges that Spectrum made false or misleading statements regarding its Pinnacle Study, which involved the drug poziotinib for lung cancer treatment [3] - Spectrum shares were delisted following the merger with Assertio Holdings, Inc. [3] Company Information - Spectrum Pharmaceuticals is a biopharmaceutical company focused on oncology treatments [2] - Investors who acquired Spectrum securities during the specified class period have until September 24, 2025, to seek appointment as lead plaintiff representatives [2] Legal Context - Berger Montague has a long history in securities class action litigation, representing individual and institutional investors since 1970 [5]

Core Viewpoint - Berger Montague PC is investigating potential securities fraud claims against Novo Nordisk A/S following a class action lawsuit filed on behalf of investors who acquired Novo securities during the specified class period from May 7, 2025, to July 28, 2025 [1][3] Summary by Sections Lawsuit Details - The lawsuit alleges that Novo Nordisk made false and misleading statements regarding the impact of compounded GLP-1 drugs, specifically underestimating the effect of the FDA's personalization exception that allows many patients to continue using compounded alternatives [3] - It is claimed that Novo overstated the likelihood of patients switching to its branded drugs, such as Ozempic® and Wegovy®, leading to significant investor losses [3] Investor Information - Investors who purchased Novo securities during the class period have until September 30, 2025, to seek appointment as a lead plaintiff representative of the class [2] Company Background - Novo Nordisk is a global pharmaceutical company headquartered in Denmark [2]